ID   UT-OC-3
AC   CVCL_A1QX
DR   Wikidata; Q105511653
RX   CelloPub=CLPUB00591;
RX   PubMed=9888470;
RX   PubMed=10754482;
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 29-06-23; Version: 4
//
RX   CelloPub=CLPUB00591;
RA   Seppanen M.;
RT   "Cytokines and gynecological cancer. In vitro effects of cytokines on
RT   ovarian, endometrial and vulvar carcinoma cells.";
RL   Thesis PhD (2000); Tampere University; Tampere; Finland.
//
RX   PubMed=9888470; DOI=10.1038/sj.bjc.6690046; PMCID=PMC2362186;
RA   Engblom P.R., Rantanen V., Kulmala J., Helenius H., Grenman S.E.;
RT   "Additive and supra-additive cytotoxicity of cisplatin-taxane
RT   combinations in ovarian carcinoma cell lines.";
RL   Br. J. Cancer 79:286-292(1999).
//
RX   PubMed=10754482; DOI=10.1530/eje.0.1420393;
RA   Seppanen M., Lin L., Punnonen J., Grenman S.E., Punnonen R., Vihko K.K.;
RT   "Regulation of UT-OC-3 ovarian carcinoma cells by cytokines:
RT   inhibitory effects on cell proliferation and activation of
RT   transcription factors AP-1 and NF-kappaB.";
RL   Eur. J. Endocrinol. 142:393-401(2000).
//